Literature DB >> 30222614

Staircase-evoked Pain May be More Sensitive Than Traditional Pain Assessments in Discriminating Analgesic Effects: A Randomized, Placebo-controlled Trial of Naproxen in Patients With Osteoarthritis of the Knee.

Roi Treister1, Erica Suzan1, Oluwadolapo D Lawal2, Nathaniel P Katz2,3.   

Abstract

OBJECTIVES: Analgesic trials often fail to show a significant effect even when medications with known efficacy are tested. This could be attributed to insufficient assay sensitivity of analgesic trials, which may be due, in part, to the insensitivity of pain-related outcome measures. The aim of this methodological study was to assess the responsiveness of evoked pain generated by the staircase procedure compared with other commonly used pain outcomes in knee osteoarthritis.
METHODS: This was a randomized, double-blind, placebo-controlled, cross-over trial of 1-week treatment of naproxen versus placebo. Participants were assigned to one of the 2 treatment sequences (naproxen-placebo or placebo-naproxen). Pain-at-rest, evoked pain using the Staircase-Evoked Pain Procedure (StEPP), pain diary, and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) data were collected before and at the end of each treatment sequence.
RESULTS: A total of 55 osteoarthritis patients (30 M, 25 F) completed the study. Among all pain assessments, evoked pain was the most sensitive outcome to detect treatment effects, with Standardized Effect Size (SES) of 0.47 followed by the WOMAC and pain-at-rest with SES of 0.43 and 0.36, respectively. Sample size calculations demonstrated that compared with spontaneous pain, the evoked pain model reduces required number of subjects by 40%. DISCUSSION: Study results support our hypothesis that evoked pain using the StEPP may demonstrate greater responsiveness to treatment effects compared with traditional pain-related outcome measures. Accordingly, these results may facilitate development and validation of other chronic pain-related evoked pain models, which could contribute to future research and development of new analgesics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30222614     DOI: 10.1097/AJP.0000000000000651

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  3 in total

1.  Study Protocol Modeling Evoked Pain in Older African Americans With Knee Osteoarthritis.

Authors:  Staja Q Booker; Angela Starkweather; Todd M Manini; Roland Staud; Roger B Fillingim
Journal:  Nurs Res       Date:  2021 Set/Oct 01       Impact factor: 2.381

2.  Research design considerations for randomized controlled trials of spinal cord stimulation for pain: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials/Institute of Neuromodulation/International Neuromodulation Society recommendations.

Authors:  Nathaniel Katz; Robert H Dworkin; Richard North; Simon Thomson; Sam Eldabe; Salim M Hayek; Brian H Kopell; John Markman; Ali Rezai; Rod S Taylor; Dennis C Turk; Eric Buchser; Howard Fields; Gregory Fiore; McKenzie Ferguson; Jennifer Gewandter; Chris Hilker; Roshini Jain; Angela Leitner; John Loeser; Ewan McNicol; Turo Nurmikko; Jane Shipley; Rahul Singh; Andrea Trescot; Robert van Dongen; Lalit Venkatesan
Journal:  Pain       Date:  2021-07-01       Impact factor: 6.961

3.  John D. Loeser Award Lecture: Size does matter, but it isn't everything: the challenge of modest treatment effects in chronic pain clinical trials.

Authors:  Shannon M Smith; Maurizio Fava; Mark P Jensen; Omar B Mbowe; Michael P McDermott; Dennis C Turk; Robert H Dworkin
Journal:  Pain       Date:  2020-09       Impact factor: 7.926

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.